Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Connor J Hagen"'
Autor:
Mandana T. Manzari, Hiroto Kiguchi, Laurie Herviou, Mariana da Silva Ferreira, Daniel A. Heller, Katia Manova-Todorova, Anas Younes, Connor J Hagen, Elisa de Stanchina, Neeta Bala Tannan, Venkatraman E. Seshan
Publikováno v:
Blood
Cancer and normal cells use multiple antiapoptotic BCL2 proteins to prevent cell death. Therapeutic targeting of multiple BCL2 family proteins enhances tumor killing but is also associated with increased systemic toxicity. Here, we demonstrate that t
Autor:
Igor Odintsov, Allan J.W. Lui, Kota Ishizawa, Isao Miyazaki, Inna Khodos, Kentaro Wakayama, Morana Vojnic, Connor J. Hagen, Qing Chang, Annalisa Bonifacio, Claudio Giuliano, Elisa de Stanchina, Emanuela Lovati, Emily Cheng, Marc Ladanyi, Romel Somwar
Publikováno v:
Journal of Clinical Oncology. 40:2024-2024
2024 Background: Patients with RET fusion-positive NSCLC have an estimated 25% incidence of CNS metastasis at diagnosis, and up to 40% during disease progression. Effective anti-RET therapy that penetrates the blood-brain barrier is essential to exte
Autor:
Igor Odintsov, Renate I. Kurth, Kota Ishizawa, Lukas Delasos, Allan J.W. Lui, Inna Khodos, Connor J. Hagen, Qing Chang, Marissa S. Mattar, Morana Vojnic, Siddharth Kunte, Annalisa Bonifacio, Claudio Giuliano, Elisa De Stanchina, Emily Cheng, Emanuela Lovati, Marc Ladanyi, Romel Somwar
Publikováno v:
Molecular Cancer Therapeutics. 20:P233-P233
Fusions involving RET receptor tyrosine kinase are a common driver of tumors across different tissue types, such as lung, thyroid, colorectal, soft tissue and others. TAS0953/HM06 (hereby referred to as HM06) is a novel 2ndgeneration RET-specific inh
Autor:
Daniel A. Heller, Venkatraman E. Seshan, Mandana T. Manzari, Mariana Da Silva Ferreira, Neeta Bala Bala, Zahra Asgari, Connor J Hagen, Anas Younes, Elisa de Stanchina, Katia Manova-Todorova
Publikováno v:
Blood. 134:305-305
Cancer and normal cell utilize multiple members of the anti-apoptotic BCL2 proteins to protect them from cell death. Selective targeting of the BCL2 protein has a limited therapeutic value in the majority of cancer patients, including lymphoma, mainl